Kirkland & Ellis acted as the lead counsel to a consortium of investors in the proposed $4.76 billion take-private of China Biologic Products Holdings, Inc. (NASDAQ: CBPO), a plasma-based biopharmaceutical company. The investor consortium comprised of Centurium Capital, CITIC Capital, Mr. Marc Chan, Hillhouse Capital, Temasek Holdings, and Mr. Joseph Chow, CEO and chairman of the board of directors of CBPO and their respective affiliates. The transaction was signed on November 19, 2020.
The Kirkland team was led by transactional partners Gary Li, Xiaoxi Lin, Sarkis Jebejian, Julia Yu, James Hu and Pierre-Luc Arsenault. The team also included debt finance partner Jacqueline Zheng, investment funds partners Justin Dolling and Jennifer Feng, capital markets partners Joshua Korff and Ben James, litigation partner Matthew Solum, tax partners Michael Beinus and Devin Heckman, and government and internal investigations partner Cori Lable. Transactional partner Joey Chau advised on the Hong Kong regulatory aspect of the transaction.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.